CDNA
HealthcareCareDx, Inc.
$19.81
+$0.67 (+3.50%)
Jan 5, 2026
Price History (1Y)
Analysis
CareDx, Inc. is a healthcare company that operates within the diagnostics and research industry. With a market capitalization of $1.05B, CareDx generates revenue of $358.00M, employing 644 individuals. The company's financial health indicates profitability, with gross margins reaching 67.6%. However, operating margin is negative at -0.2%, while profit margin stands at 19.7%. Returns on equity and assets are also mixed, with a return on equity of 24.1% contrasting with a return on assets of -4.0%. The company maintains a relatively strong balance sheet, boasting $194.22M in cash against $27.64M in debt. CareDx's valuation metrics reveal a P/E ratio of 14.89 (TTM) and a forward P/E of 22.22. Revenue growth has been steady at 20.7% year-over-year, but earnings growth is not specified. The company does not pay dividends, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About CareDx, Inc.
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $1.05B
- P/E Ratio
- 14.89
- 52-Week High
- $25.95
- 52-Week Low
- $10.96
- Avg Volume
- 943.22K
- Beta
- 2.49
Company Info
- Industry
- Diagnostics & Research
- Exchange
- NGM
- Country
- United States
- Employees
- 644